ALPEGA
16.7.2024 10:01:29 CEST | Business Wire | Press release
Alpega is excited to announce the return of Connecta, the premier networking event in the European road transport sector, celebrating its 14th edition. Scheduled for October 10th and 11th, 2024, at the prestigious Marriott Auditorium Conference Center in Madrid, this year's event promises to be the most comprehensive and impactful yet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716487251/en/
(Photo: Business Wire)
Unparalleled Networking Opportunities
With over 500 professionals from across Europe expected to attend, Connecta 2024 will offer unmatched networking opportunities. Participants can generate significant business prospects within a single day, thanks to a meticulously planned agenda of networking activities. This event brings together the major players in the market, offering attendees a unique platform to engage in meaningful conversations and forge valuable connections.
A Full Logistics Network Representation
For the first time, Connecta 2024 will feature all logistics network participants, including carriers, freight forwarders, and shippers. This comprehensive representation ensures a holistic view of the industry, facilitating deeper insights and collaboration across different segments of the transport sector.
Showcasing the Latest Innovations
Connecta 2024 will also be a platform to showcase the latest innovations in the logistics sector. Attendees will have the opportunity to explore cutting-edge solutions and technologies that are transforming the industry, providing valuable insights into future trends and advancements.
Expanded Agenda with Key Panels and Workshops
The 2024 edition of Connecta boasts an expanded agenda, beginning on Thursday afternoon with a series of key panels and workshops. We are excited to confirm an inaugural session with Boston Consulting Group (BCG), led by Jesus Montero, Lead Knowledge Analyst in Logistics, presenting insightful analysis on industry trends alongside major sector players. Additionally, attendees can look forward to a networking workshop led by the renowned Jose Maria Salles, providing practical tools and strategies for effective networking.
Why Attend Connecta 2024?
“Connecta is more than just a networking event; it's a pivotal moment for the European logistics community to come together, share insights, and drive innovation. This year's edition will be our most impactful yet, offering unparalleled opportunities to connect, learn, and grow,” said Todd DeLaughter, CEO of Alpega.
- Engage with Industry Leaders: Meet and converse with top influencers and decision-makers in the European road transport industry.
- Generate Business Opportunities: Utilize tailored networking activities to create valuable business prospects in a single day.
- Gain Industry Insights: Attend sessions and panels led by industry experts, including a detailed analysis of current trends by BCG.
- Comprehensive Network Representation: Benefit from the presence of carriers, logistics operators, and shippers, offering a complete view of the transport chain.
- Discover Innovations: Explore the latest technologies and solutions shaping the future of logistics.
Don’t miss this unparalleled opportunity to connect, learn, and grow within the European road transport sector. Join us at Connecta 2024 and be part of the conversation shaping the future of the industry.
Registration and Additional Information
For more details and to register for Connecta 2024, please visit our official website Alpega Connecta. Special early bird prices are available until July 31st.
About Alpega
Alpega is a global leader in logistics SaaS software, dedicated to delivering comprehensive end-to-end solutions for all transport requirements. Our mission is to empower shippers, forwarders, and carriers through efficient digitalization, addressing today’s logistics challenges and driving smarter logistics for a greener tomorrow.
Leveraging extensive carrier-based assets, Alpega provides tangible benefits in Transport Execution, Freight Planning, Freight Sourcing and Payment, Dock Scheduling, and Data Insights. As the only SaaS provider offering Transport Management Systems (TMS) for shippers, and with an 80,000-strong open carrier network that covers about 10% of all commercial trucks in Europe, we lead in innovation and efficiency.
Our connectivity extends through three premier freight exchanges in Europe, with notable leadership in Iberia, Romania, Central, and Southeastern European regions, facilitating seamless matching of freight loads with transportation capacity.
With over three decades of transportation expertise, we help businesses streamline their supply chain planning and execution, reducing costs and increasing visibility. Our community of 80,000 carriers and 200,000 members is seamlessly connected daily, efficiently managing vital transport operations. This network harnesses the power of collective intelligence, driving data-driven insights and optimizations across the logistics ecosystem, and creating a network effect that adds significant value for our customers. Operating in 80 countries, Alpega boasts a diverse team of over 450+ professionals representing 31 nationalities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716487251/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom